


PHARMACEUTICAL 2021



OptiNose Inc. Rank 257 of 409





PHARMACEUTICAL 2021



OptiNose Inc. Rank 257 of 409

The relative strengths and weaknesses of OptiNose Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OptiNose Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 92% points. The greatest weakness of OptiNose Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is -215%, being 140% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	180,652
Cost of Goods Sold	7,520
Intangible Assets	0
Liabilities, Current	52,172
Liabilities, Non-Current	125,202
Other Assets	6,133
Other Compr. Net Income	-37
Other Expenses	13,008
Other Liabilities	4,651
Other Net Income	442
Property and Equipment	2,028
Research and Development	23,378
Revenues	49,117
Selling, General and Administrative Expense	105,438

Output Variable	Value in 1000 USD
Assets	188,813
Liabilities	182,025
Expenses	149,344
Stockholders Equity	6,788
Net Income	-99,785
Comprehensive Net Income	-99,804
Economic Capital Ratio	-215%